Biotech in 2019: Gene Therapies, Cancer Immunotherapies, and mRNA Investing in early-stage biotechnology companies requires great skill and patience (luck is always helpful as well). 10 MIN READ 12.4.2018
Regeneron and bluebird bio to Collaborate on Cancer Immunotherapy Regeneron also investing $100 million in bluebird bio at 59% premium to Aug. 3rd closing price. 3 MIN READ 08.6.2018
